SI2459555T1 - Postopek kristalizacije rivaroksabana - Google Patents

Postopek kristalizacije rivaroksabana

Info

Publication number
SI2459555T1
SI2459555T1 SI201032103T SI201032103T SI2459555T1 SI 2459555 T1 SI2459555 T1 SI 2459555T1 SI 201032103 T SI201032103 T SI 201032103T SI 201032103 T SI201032103 T SI 201032103T SI 2459555 T1 SI2459555 T1 SI 2459555T1
Authority
SI
Slovenia
Prior art keywords
rivaroxaban
crystallization
processes
Prior art date
Application number
SI201032103T
Other languages
English (en)
Inventor
Silvo Zupancic
Anica Pecavar
Original Assignee
Krka, D.D., Novo Mesto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Krka, D.D., Novo Mesto filed Critical Krka, D.D., Novo Mesto
Publication of SI2459555T1 publication Critical patent/SI2459555T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SI201032103T 2009-07-31 2010-07-30 Postopek kristalizacije rivaroksabana SI2459555T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SI200900218 2009-07-31
EP10740170.5A EP2459555B1 (en) 2009-07-31 2010-07-30 Processes for crystallization of rivaroxaban
PCT/EP2010/004688 WO2011012321A1 (en) 2009-07-31 2010-07-30 Processes for crystallization of rivaroxaban

Publications (1)

Publication Number Publication Date
SI2459555T1 true SI2459555T1 (sl) 2022-03-31

Family

ID=42831508

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201032103T SI2459555T1 (sl) 2009-07-31 2010-07-30 Postopek kristalizacije rivaroksabana

Country Status (7)

Country Link
EP (1) EP2459555B1 (sl)
EA (1) EA031064B2 (sl)
ES (1) ES2905760T3 (sl)
HU (1) HUE057769T2 (sl)
PL (1) PL2459555T3 (sl)
SI (1) SI2459555T1 (sl)
WO (1) WO2011012321A1 (sl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20156397B (en) 2011-05-06 2015-11-10 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Process for the preparation of a rivaroxaban and intermediates formed in said process
CN102827154B (zh) * 2011-06-14 2015-04-22 上海科胜药物研发有限公司 一种合成利伐沙班中间体4-{4-[(5s)-5-(氨基甲基)-2-氧代-1,3-恶唑烷-3-基]苯基}吗啉-3-酮的方法
CN103012388B (zh) * 2011-09-20 2016-01-20 联化科技(上海)有限公司 一种利伐沙班及其中间体的制备方法,以及中间体化合物
EP2573084A1 (en) * 2011-09-22 2013-03-27 Enantia, S.L. Novel crystalline forms of rivaroxaban and processes for their preparation
EP2844654B1 (en) 2012-05-02 2021-03-10 Symed Labs Limited Improved process for preparing rivaroxaban using novel intermediates
WO2014020458A1 (en) * 2012-08-01 2014-02-06 Alembic Pharmaceuticals Limited Improved process for preparation of rivaroxaban
PL2935255T3 (pl) 2012-12-21 2018-01-31 Farma Grs D O O Sposób wytwarzania rywaroksabanu
AU2013368847B2 (en) 2012-12-26 2017-03-16 Wanbury Ltd. Aldehyde derivative of substitute oxazolidinones
US9394292B2 (en) 2012-12-26 2016-07-19 Wanbury Ltd. Rivaroxaban intermediate and preparation thereof
WO2014155259A2 (en) * 2013-03-25 2014-10-02 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for the preparation of rivaroxaban
CN104109158A (zh) * 2013-04-16 2014-10-22 上海医药工业研究院 一种纯化利伐沙班的方法
CN104650058A (zh) * 2013-11-23 2015-05-27 天津市汉康医药生物技术有限公司 利伐沙班一水合物化合物
WO2015104605A1 (en) 2014-01-08 2015-07-16 Wockhardt Limited A process for preparing rivaroxaban or a pharmaceutically acceptable salt thereof
IN2014CH00290A (sl) 2014-01-23 2015-08-14 Symed Labs Ltd
WO2015198259A1 (en) 2014-06-26 2015-12-30 Erregierre S.P.A. Process for the synthesis of rivaroxaban and intermediate for the production thereof
CN104211693B (zh) * 2014-08-07 2017-02-22 成都百裕制药股份有限公司 一种利伐沙班晶型及其制备方法与用途
CN105503849B (zh) * 2014-09-26 2019-10-08 重庆华邦胜凯制药有限公司 一种制备小粒度利伐沙班原料药的方法
PL3209661T3 (pl) 2014-10-22 2021-08-16 Zakłady Farmaceutyczne Polpharma Sa Sposób wytwarzania polimorfu rywaroksabanu
CN107778303B (zh) * 2016-08-27 2020-03-24 鲁南制药集团股份有限公司 利伐沙班的精制方法
CN108344832B (zh) * 2017-12-28 2021-03-09 江苏悦兴医药技术有限公司 一种主成分与其杂质完全分离的检测方法
CN109142601B (zh) * 2018-10-25 2021-03-12 重庆华邦胜凯制药有限公司 一种分离利伐沙班中间体及其杂质的方法
CN111518092B (zh) * 2019-02-01 2022-12-20 鲁南制药集团股份有限公司 利伐沙班乙酸溶剂合物及其制备方法
CN115745984A (zh) * 2019-04-02 2023-03-07 北京四环制药有限公司 一种制备易于粉碎的利伐沙班及其制备方法
CN111721858B (zh) * 2020-06-03 2022-07-01 杭州华东医药集团新药研究院有限公司 一种测定利伐沙班中基因毒性杂质的方法
GR1010231B (el) * 2021-03-24 2022-05-10 Φαρματεν Α.Β.Ε.Ε., Φαρμακευτικο σκευασμα που περιλαμβανει ριβαροξαμπανη και μεθοδος παρασκευης αυτου
EP4201933A1 (en) 2021-12-23 2023-06-28 Zaklady Farmaceutyczne Polpharma S.A. Crystallisation process for rivaroxaban

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
DE10300111A1 (de) * 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE102004002044A1 (de) 2004-01-15 2005-08-04 Bayer Healthcare Ag Herstellverfahren
SG166126A1 (en) 2005-10-04 2010-11-29 Bayer Schering Pharma Ag Novel polymorphous form and the amorphous form of 5-chloro-n-({(5s)-2-oxo- 3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide
WO2009074249A1 (en) * 2007-12-11 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Oxazolidinones for the treatment and/or prophylaxis of heart failure
US20100168111A1 (en) 2008-12-31 2010-07-01 Apotex Pharmachem Inc. Polymorphic form of 5 chloro n {[(5s) 2 oxo 3 [4 (3 oxomorpholin 4 yl)phenyl]oxa-zolidin 5 yl]-methyl}thiophene 2 carboxamide
WO2014020458A1 (en) 2012-08-01 2014-02-06 Alembic Pharmaceuticals Limited Improved process for preparation of rivaroxaban

Also Published As

Publication number Publication date
PL2459555T3 (pl) 2022-03-28
EA201290074A1 (ru) 2012-07-30
ES2905760T3 (es) 2022-04-12
WO2011012321A1 (en) 2011-02-03
EP2459555A1 (en) 2012-06-06
EP2459555B1 (en) 2021-11-03
HUE057769T2 (hu) 2022-06-28
EA031064B1 (ru) 2018-11-30
EA031064B2 (ru) 2020-07-01

Similar Documents

Publication Publication Date Title
SI2459555T1 (sl) Postopek kristalizacije rivaroksabana
IL283038A (en) Processes for preparing intermediates for protein tyrosine kinase inhibitors
HK1254977A1 (zh) 索非布韋(sofosbuvir)的結晶形式
ZA201600646B (en) Process for beta-lactone production
PT2634191E (pt) Processo para preparar derivados de tienopirimidinadiona
EP2480523A4 (en) PROCESS FOR THE PRODUCTION OF N-ACYLBPHENYLALANINE
EP2439312A4 (en) PROCESS FOR PRODUCING REDUCED GLUTATHION
EP2407461A4 (en) PROCESS FOR PREPARING 1-ALKYL-5-BENZOYL-1H-TETRAZOL DERIVATIVES
IL216942A0 (en) Process for the manufacture of alkenones
ZA201202343B (en) Process for the preparation of lenalidomide
EP2292579A4 (en) PROCESS FOR THE PRODUCTION OF HALOGENATED FLUOROETHERS
EP2400848A4 (en) CRYSTALLIZATION OF PHARMACEUTICAL COMPOUNDS
ZA201109045B (en) Crystalline form of pemirolast
EP2514719A4 (en) PROCESS FOR SYNTHESIS OF AMMONIA
EP2423187A4 (en) PROCESS FOR PRODUCING N-ALCOXYCARBONYL-tert-LEUCINS
EP2491044A4 (en) IMPROVED METHOD FOR THE PREPARATION OF CLOPIODOGREL BISULFATE IN THE CRYSTAL FORM 1
EP2511234A4 (en) PROCESS FOR THE PRODUCTION OF DDR ZEOLITE
EP2514783A4 (en) METHOD FOR PRODUCING AN ORGANOPOLYSILOXAN COMPOUND
EP2423212A4 (en) PROCESS FOR PREPARING A 2-AZAADAMANTAN COMPOUND FROM A BICYCLOCARBAMATE COMPOUND
EP2281780A4 (en) PROCESS FOR PREPARING SILICON
EP2251329A4 (en) PROCESS FOR THE PRODUCTION OF 3-AMINO-2-CHLORO-6-TRIFLUOROMETHYLPYRIDINE
EP2514784A4 (en) PROCESS FOR THE PRODUCTION OF ORGANOPOLYSILOXANE COMPOUND
GB0906289D0 (en) Processes for making isoxazoline derivatives
GB0913427D0 (en) Compounds for treatment of imflammation
EP2514302A4 (en) PROCESS FOR PRODUCING MULTI-PETAL CYCLAMEN